AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24520780 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 204
Study 23140056 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Acupuncture
Number of subjects: 74
Study 23140056 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 74
Study 20153280 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled running training based on interval training and speed exercises
Number of subjects: 85
Study 20153280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retraining)
Number of subjects: 85
Study 18576337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 12 weeks
Number of subjects: 46
Study 18576337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16023067 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy group (Gr I)
Number of subjects: 56
Study 16023067 — intervention group
Group type: COMPARATOR
Intervention: Control group (Gr II)
Number of subjects: 56
Study 11926601 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 11926601 — intervention group
Group type: COMPARATOR
Intervention: Control group interventions
Number of subjects: 0
Study 11117863 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy (50 Gy in 25 fractions)
Number of subjects: 0
Study 11117863 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiation plus brachytherapy boost (minimum peripheral tumor dose of 60 Gy)
Number of subjects: 0
Study 11117863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Conventional radiation therapy and Conventional radiation plus brachytherapy boost)
Number of subjects: 0
Study 8818259 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage procedure (removal at one visit)
Number of subjects: 100
Study 8818259 — intervention group
Group type: COMPARATOR
Intervention: Two-stage procedure (removal in two stages, 3-4 weeks apart)
Number of subjects: 100
Study 8818259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 1428296 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alpha-glycerylphosphorylcholine (alpha-GPC) 1,000 mg
Number of subjects: 12
Study 1428296 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (CTC) 1,000 mg
Number of subjects: 12
Study 1428296 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug administration)
Number of subjects: 12
Study 6429319 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral metoprolol (beta-blockade)
Number of subjects: 6
Study 6429319 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6
Study 29236547 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable story (snus framed as a safer alternative)
Number of subjects: 1008
Study 29236547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed story (described potential risks and harm-reduction benefits)
Number of subjects: 1008
Study 29236547 — intervention group
Group type: COMPARATOR
Intervention: Cautious story (described snus risks)
Number of subjects: 1008
Study 29236547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no article)
Number of subjects: 1008
Study 29236547 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable story
Number of subjects: 1008
Study 29236547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed story
Number of subjects: 1008
Study 29236547 — intervention group
Group type: COMPARATOR
Intervention: Cautious story
Number of subjects: 1008
Study 29236547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1008
Study 30296453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group (RTG, 12 weeks, 3 times a week)
Number of subjects: 44
Study 30296453 — intervention group
Group type: COMPARATOR
Intervention: Active control group (CG, stretching classes, 12 weeks, once a week)
Number of subjects: 44
Study 30296453 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group (RTG)
Number of subjects: 44
Study 27004617 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 portions of fruit and vegetable (FV) daily for 12 weeks
Number of subjects: 62
Study 27004617 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 portions of fruit and vegetable (FV) daily for 12 weeks
Number of subjects: 62
Study 27004617 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 portions of fruit and vegetable (FV) daily for 12 weeks
Number of subjects: 62
Study 25236363 — intervention group
Group type: EXPERIMENTAL
Intervention: FibNVT/VF1
Number of subjects: 568
Study 25236363 — intervention group
Group type: EXPERIMENTAL
Intervention: FibNVT/VF2
Number of subjects: 568
Study 21704995 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) with a locked volar plate
Number of subjects: 75
Study 21704995 — intervention group
Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 75
Study 20445490 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-lubricated non-hydrophilic catheter
Number of subjects: 25
Study 20445490 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated catheter
Number of subjects: 25
Study 20445490 — intervention group
Group type: COMPARATOR
Intervention: PVC catheter
Number of subjects: 25
Study 17328985 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFNalpha monotherapy (180 microg weekly)
Number of subjects: 42
Study 17328985 — intervention group
Group type: COMPARATOR
Intervention: Peg-IFNalpha and ribavirin (up to maximum tolerated dose for 48 weeks)
Number of subjects: 42
Study 16245642 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA/PLA
Number of subjects: 20
Study 16245642 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA/PLA and resorbable hydroxylapatite
Number of subjects: 20
Study 16245642 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG
Number of subjects: 20
Study 16245642 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG and resorbable hydroxylapatite
Number of subjects: 20
Study 16245642 — intervention group
Group type: COMPARATOR
Intervention: Flap debridement alone
Number of subjects: 20
Study 11712808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG
Number of subjects: 121
Study 11712808 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring BCG with urinary tumor markers
Number of subjects: 121
Study 9222938 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mmol NaCl/day (slow sodium)
Number of subjects: 103
Study 9222938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 8381164 — intervention group
Group type: EXPERIMENTAL
Intervention: Early thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the first cycle of etoposide and cisplatin (EP) (week 3)
Number of subjects: 308
Study 8381164 — intervention group
Group type: COMPARATOR
Intervention: Late thoracic irradiation (TI) - 40 Gy in 15 fractions over 3 weeks concurrent with the last cycle of etoposide and cisplatin (EP) (week 15)
Number of subjects: 308
Study 3617240 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave coagulation followed by transurethral resection (TUR)
Number of subjects: 35
Study 3617240 — intervention group
Group type: COMPARATOR
Intervention: Conventional TUR
Number of subjects: 35
Study 2173394 — intervention group
Group type: EXPERIMENTAL
Intervention: Acivicin
Number of subjects: 56
Study 2173394 — intervention group
Group type: COMPARATOR
Intervention: 4'deoxydoxorubicin (esorubicin)
Number of subjects: 56
Study 4898563 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoestrol, 45 mg, single injection
Number of subjects: 0
Study 4898563 — intervention group
Group type: COMPARATOR
Intervention: Stilboestrol, customary oral course
Number of subjects: 0
Study 31141275 — intervention group
Group type: EXPERIMENTAL
Intervention: Body lotion with 3HFWC
Number of subjects: 0
Study 31141275 — intervention group
Group type: COMPARATOR
Intervention: Body lotion vehiculum (control)
Number of subjects: 0
Study 31141275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand cream with 3HFWC
Number of subjects: 0
Study 31141275 — intervention group
Group type: COMPARATOR
Intervention: Commercial hand cream (control)
Number of subjects: 0
Study 31333262 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of future access to recorded lectures
Number of subjects: 78
Study 31333262 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of no future access to recorded lectures
Number of subjects: 78
Study 31333262 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewing recorded lectures
Number of subjects: 78
Study 28791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneic Oxygenation (AO)
Number of subjects: 206
Study 28791755 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 206
Study 26508709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (2.5, 5, or 7.5 mg bid)
Number of subjects: 0
Study 26508709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26508709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine and Placebo
Number of subjects: 0
Study 24113671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose diclofenac submicron particle capsules 35 mg TID
Number of subjects: 428
Study 24113671 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose diclofenac submicron particle capsules 18 mg TID
Number of subjects: 428
Study 24113671 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 428
Study 24113671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study 21949275 — intervention group
Group type: EXPERIMENTAL
Intervention: Search-supported group (bibliographic assistance)
Number of subjects: 809
Study 21949275 — intervention group
Group type: EXPERIMENTAL
Intervention: Search-supported group (hand-delivered information)
Number of subjects: 809
Study 21949275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 809
Study 19321581 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye whole‐grain/bran
Number of subjects: 17
Study 19321581 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat products
Number of subjects: 17
Study 16289498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 1: 20% of calorie requirements taken as E028 extra liquid)
Number of subjects: 50
Study 16289498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 2: 50% of calorie requirements taken as E028 extra liquid)
Number of subjects: 50
Study 16289498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 3: 75% of calorie requirements taken as E028 extra liquid)
Number of subjects: 50
Study 16289498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 4: 50% of calorie requirements taken as E028 extra powder)
Number of subjects: 50
Study 16289498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Group 5: 50% of calorie requirements taken as Emsogen powder)
Number of subjects: 50
Study 15304586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg before and 6 and 12 hours after each injection
Number of subjects: 84
Study 15304586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg before and 6 and 12 hours after each injection
Number of subjects: 84
Study 15304586 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg daily for 1 week, plus tapering
Number of subjects: 84
Study 11182530 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patches (N = 18)
Number of subjects: 38
Study 11182530 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches (N = 20)
Number of subjects: 38
Study 9217952 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal amnioinfusion
Number of subjects: 18
Study 9217952 — intervention group
Group type: COMPARATOR
Intervention: Control (historic cohort managed expectantly)
Number of subjects: 18
Study 9217952 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful amnioinfusion (infused solution alleviated oligohydramnios for > 48 hours)
Number of subjects: 18
Study 9217952 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful amnioinfusion (infused solution rapidly lost)
Number of subjects: 18
Study 7983119 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐V Impulse System foot pump activated during periods of stasis
Number of subjects: 10
Study 7983119 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure of the acetabulum by distraction of the femur with a hook
Number of subjects: 10
Study 7983119 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate exposure of the femoral shaft by adduction, flexion and either internal or external rotation
Number of subjects: 10
Study 7983119 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 3110524 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg RO 15-1788
Number of subjects: 0
Study 3110524 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg RO 15-1788
Number of subjects: 0
Study 3110524 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg RO 15-1788
Number of subjects: 0
Study 3110524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28782145 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal 150 mg
Number of subjects: 8
Study 28782145 — intervention group
Group type: COMPARATOR
Intervention: Camicinal 50 mg
Number of subjects: 8
Study 28782145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 27439601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell (BMC) infusion
Number of subjects: 101
Study 27439601 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art therapy (control group)
Number of subjects: 101
Study 25220033 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity (AS)
Number of subjects: 523
Study 23632913 — intervention group
Group type: EXPERIMENTAL
Intervention: ISM (Internet‐based stress management program)
Number of subjects: 0
Study 23632913 — intervention group
Group type: EXPERIMENTAL
Intervention: ISM+ (ISM plus online message board)
Number of subjects: 0
Study 23632913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22082672 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 50 mg/d
Number of subjects: 486
Study 22082672 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 100 mg/d
Number of subjects: 486
Study 22082672 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 300 mg/d
Number of subjects: 486
Study 22082672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 200 mg/d (after loading dose of 600 mg/d for 10 days)
Number of subjects: 486
Study 22082672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 19408831 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg body weight s.c. twice daily
Number of subjects: 60
Study 19408831 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (Heparin - 'Biochemie' 25.000 IU/5 ml)
Number of subjects: 60
Study 16984771 — intervention group
Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET)
Number of subjects: 45
Study 16984771 — intervention group
Group type: COMPARATOR
Intervention: Triple embryo transfer (TET)
Number of subjects: 45
Study 15182982 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% maximal isometric contraction of the neck extensors for 10 min
Number of subjects: 10
Study 15182982 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% maximal isometric contraction of the neck extensors for 15 min
Number of subjects: 10
Study 15182982 — intervention group
Group type: COMPARATOR
Intervention: Control measurements (sitting quietly for 5, 10, and 15 min)
Number of subjects: 10
Study 11318080 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily, titrated to 20 mg once daily and then 40 mg once daily as needed.
Number of subjects: 478
Study 11318080 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin 20 mg once daily, titrated to 40 mg once daily and then 40 mg twice daily as needed.
Number of subjects: 478
Study 11318080 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin in CHD subgroup.
Number of subjects: 478
Study 11318080 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin in CHD subgroup.
Number of subjects: 478
Study 11318080 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin in MRF subgroup.
Number of subjects: 478
Study 11318080 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin in MRF subgroup.
Number of subjects: 478
Study 11318080 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin group.
Number of subjects: 478
Study 11318080 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin group.
Number of subjects: 478
Study 11318080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 478
Study 9159677 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mm sutureless clear corneal incision
Number of subjects: 200
Study 9159677 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mm clear corneal incision with absorbable suture
Number of subjects: 200
Study 9159677 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mm clear corneal incision with single radial suture (Group B1)
Number of subjects: 200
Study 9159677 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mm clear corneal incision with X suture (Group B2)
Number of subjects: 200
Study 8226146 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive margin group (field margins exceeded protocol specification)
Number of subjects: 832
Study 8226146 — intervention group
Group type: COMPARATOR
Intervention: Per protocol group (field margins within protocol specification)
Number of subjects: 832
Study 8226146 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive margin group
Number of subjects: 832
Study 8226146 — intervention group
Group type: COMPARATOR
Intervention: Per protocol group
Number of subjects: 832
Study 3311275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily for 3 days as prophylaxis
Number of subjects: 0
Study 3311275 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31188242 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 28
Study 31188242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 27943311 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 200 mg QD
Number of subjects: 350
Study 27943311 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 400 mg QD
Number of subjects: 350
Study 27943311 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir 1000 mg TID
Number of subjects: 350
Study 25264861 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle ischemic preconditioning (IPT)
Number of subjects: 11
Study 25264861 — intervention group
Group type: COMPARATOR
Intervention: Control sham test (ST)
Number of subjects: 11
Study 25264861 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference test (RT)
Number of subjects: 11
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: MHA (microparticle size) coated non-etched implants (G1)
Number of subjects: 40
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA (nanoparticle size) coated non-etched implants (G2)
Number of subjects: 40
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: MHA coated after citric acid conditioning (G3)
Number of subjects: 40
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA coated after citric acid conditioning (G4)
Number of subjects: 40
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: MHA mixed with whole human blood without surface treatment (G5)
Number of subjects: 40
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA mixed with whole human blood without surface treatment (G6)
Number of subjects: 40
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: MHA treated with citric acid and clot-blended (G7)
Number of subjects: 40
Study 22554294 — intervention group
Group type: EXPERIMENTAL
Intervention: NHA treated with citric acid and clot-blended (G8)
Number of subjects: 40
Study 21216835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (MONO)
Number of subjects: 150
Study 21216835 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and mycophenolate mofetil therapy (COMBO)
Number of subjects: 150
Study 18053320 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 µg BID for 30 weeks, then 5 µg BID for 4 weeks, then 10 µg BID for ≥ 3 years
Number of subjects: 217
Study 18053320 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 217
Study 17059921 — intervention group
Group type: EXPERIMENTAL
Intervention: Blake drains (19F)
Number of subjects: 199
Study 17059921 — intervention group
Group type: COMPARATOR
Intervention: Portex drains (28F)
Number of subjects: 199
Study 12571543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-monitored structured care program with uptitration of enalapril to a target dose of 10 mg twice a day
Number of subjects: 145
Study 12571543 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 145
Study 12571543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-monitored structured care program
Number of subjects: 145
Study 12571543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-monitored structured care program and Standard care
Number of subjects: 145
Study 10638714 — intervention group
Group type: EXPERIMENTAL
Intervention: ImPACT program
Number of subjects: 237
Study 10638714 — intervention group
Group type: COMPARATOR
Intervention: Attention-control program on goal-setting
Number of subjects: 237
Study 8717103 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week
Number of subjects: 185
Study 8717103 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 25 mg/week
Number of subjects: 185
Study 8717103 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 185
Study 1458072 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin in fat emulsion (2 g/l fat emulsion)
Number of subjects: 22
Study 1458072 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin in glucose (5% glucose)
Number of subjects: 22